Anixa Biosciences, Inc. (ANIX) said a genomic variant analysis indicates that the company's potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2. The company's program in collaboration with MolGenie, focuses on identifying small molecule inhibitors of Mpro, the main protease of the virus.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

Anixa Biosciences, Inc. (ANIX) said a genomic variant analysis indicates that the company's potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2. The company's program in collaboration with MolGenie, focuses on identifying small molecule inhibitors of Mpro, the main protease of the virus.

RTTNews | Aug 25, 2021 08:53AM EDT

08:52 Wednesday, August 25, 2021 (RTTNews.com) - Anixa Biosciences, Inc. (ANIX) said a genomic variant analysis indicates that the company's potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2. The company's program in collaboration with MolGenie, focuses on identifying small molecule inhibitors of Mpro, the main protease of the virus.

Amit Kumar, CEO of Anixa Biosciences, said: "While this program is relatively early-stage in development, we have already received inbound calls from pharmaceutical companies and funding agencies interested in collaborating at the right time."

Shares of Anixa Biosciences were up 14% in pre-market trade on Wednesday.

Read the original article on RTTNews ( https://www.rttnews.com/3221018/anixa-theoretical-study-shows-effectiveness-of-its-compounds-against-delta-variant.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved